MS and Demyelinating Disorders

Bryant Robinson, senior manager of government relations at the National MS Society, discussed how telehealth access has become vital for patients with multiple sclerosis who often lack nearby specialist care.

After 48 weeks of continued treatment, those in the high-dose frexalimab group showed a 41% reduction in neurofilament light.

Data from the large-scale, phase 3 OCARINA 2 trial was the basis for the approval.

Negroski detailed a real-world analysis on cladribine, an FDA-approved DMT, in an aging population of MS, and the recent increase in research for older populations with the disease.

In this episode, Negroski gave insight on the impact of health care-related social determinants of health, their impact on brain structure and aging in MS, and where efforts should be directed towards going forward.

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy/Dravet syndrome.

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed how combining advanced therapies with lifestyle modifications can improve outcomes and slow disease progression in patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 28, 2024.

In this segment, Negroski comments on the realism behind wearing off effect of treatments, specifically ocrelizumab, and how clinicians may work around some of these issues.

Negroski discussed some of the takeaways from an analysis of patients with stable MS who chose to switch from natalizumab to other, more moderate-efficacy oral disease-modifying therapies.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Alzheimer disease/dementia.

Patients treated with at least 12.5 mg/day of oral prednisone for at least 3 months had an 88% reduction in the risk of relapse compared with those who did not receive this regimen.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 21, 2024.

In this conversation, Negroski provides commentary on the role of lymphocyte counts and specifically a study evaluating changes in these counts for patients switching between dimethyl and diroximel fumarates.

Donald Negroski, MD, shared thoughts on retrospective data assessing patients with multiple sclerosis who switched from S1P-modulating agents to ozanimod, another approved disease-modifying therapy.

The clinical research director of the UCSF Multiple Sclerosis Center discussed findings from the end-of-study analysis assessing inebilizumab which revealed a significant reduction in attack rates among patients with NMOSD over time. [WATCH TIME: 3 minutes]

Douglas A. Wadja, PhD, an assistant professor of neurology at Cleveland State University, detailed a study assessing an electrical nerve stimulation approach to alleviate gait dysfunction in patients with MS.

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor of neurology at UCSF Weill Institute for Neurosciences talked about a study that explored the use of commercial wearable devices to monitor and manage bladder dysfunction in multiple sclerosis. [WATCH TIME: 6 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on narcolepsy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 14, 2024.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Anthony Feinstein, PhD, FRCPC, MBBCh; Brian G. Weinshenker, MD; Douglas A. Wajda, PhD; Le Hua, MD; and Eoin P. Flanagan, MB, BCh. [LISTEN TIME: 22 minutes]